Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)

Balabanov, Roumen; Lisak, Deena; Beaumont, Thomas L.; Lisak, Robert P.; Dore‐Duffy, Paula

doi:10.1128/cdli.8.6.1196-1203.2001

Cited by 23 publications

(18 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…suPAR was already described as a valuable indicator of the activation of the immune system in immune-related rheumatic diseases including rheumatoid arthritis, systemic lupus erythematosus, and further autoimmune diseases such as multiple sclerosis [10,15]. We also found higher suPAR levels in SSc as the consequence of the chronic inflammation and autoimmune mechanisms.…”

Section: Discussionmentioning

confidence: 55%

Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis

Legány¹,

Toldi²,

Distler³

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 55%

Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis

Legány¹,

Toldi²,

Distler³

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…High levels of uPA, uPA receptor (uPAR), and PAI-1 occur in acute MS lesions in association with mononuclear cells and foamy macrophages suggestive of a role in facilitation of CNS cellular infiltration [7,55,99]. uPAR is constitutively expressed by leukocytes, including monocytes and activated T cells, and plays a prominent role in adhesion and migration to sites of inflammation by interactions with vitronectin and integrins [259,283].…”

Section: Plasminogenmentioning

confidence: 99%

The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

Scarisbrick

2008

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

An array of studies implicate different classes of protease and their endogenous inhibitors in multiple sclerosis (MS) pathogenesis based on expression patterns in MS lesions, sera, and/or cerebrospinal fluid (CSF). Growing evidence exists regarding their mechanistic roles in inflammatory and neurodegenerative aspects of this disease. Proteolytic events participate in demyelination, axon injury, apoptosis, and development of the inflammatory response including immune cell activation and extravasation, cytokine and chemokine activation/inactivation, complement activation, and epitope spreading. The potential significance of proteolytic activity to MS therefore relates not only to their potential use as important biomarkers of disease activity, but additionally as prospective therapeutic targets. Experimental data indicate that understanding the net physiological consequence of altered protease levels in MS development and progression necessitates understanding protease activity in the context of substrates, endogenous inhibitors, and proteolytic cascade interactions, which together make up the MS degradome. This review will focus on evidence regarding the potential physiologic role of those protease families already identified as markers of disease activity in MS; that is, the metallo-, serine, and cysteine proteases.

show abstract

“…However, activation of the immune system and the development of an inflammatory response lead to elevated plasma suPAR concentrations. The plasma level of suPAR is increased in infectious [5,6] , autoimmune [7] , neoplastic [8] and pregnancy-related [9] diseases. Interestingly, in all of these conditions suPAR concentrations are directly proportional to a worse prognosis of the disease [5,6,8,10] .…”

Section: Introductionmentioning

confidence: 99%

Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission

Toldi

Bekő

Kádár

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the assessment of systemic inflammation. We aimed to evaluate suPAR for the assessment of inflammatory activity in rheumatoid arthritis (RA) patients in remission. Methods: In our cross-sectional study we measured plasma suPAR and C-reactive protein (CRP) levels as well as erythrocyte sedimentation rate (ESR) in 120 RA patients at various stages of disease activity and 29 healthy agematched controls. Results: suPAR, CRP and ESR values were higher in RA patients compared to healthy individuals. When suPAR levels were analyzed according to DAS28 scores of RA patients, suPAR level in the subgroup with DAS28 ≤ 2.6 was lower than in the subgroup with DAS28 > 2.6, but still higher than in controls [4.45 (3.33 -5.56) ng/mL vs. 3.66 (3.10 -4.67) ng/mL vs. 2.80 (2.06 -3.42) ng/mL, p < 0.0001, median (interquartile range)]. In contrast, CRP and ESR values were comparable in the subgroup with DAS28 ≤ 2.6 and in healthy individuals. We further analyzed the correlation between the number of tender and/or swollen joints and suPAR levels in RA patients in remission. suPAR values were significantly higher in patients with four tender and/or swollen joints than in patients with 2 -3 or 0 -1 tender and/or swollen joints. Conclusions: While CRP and ESR values indicate remission of the chronic inflammatory process in RA, suPAR values are still elevated compared to healthy individuals. suPAR might be particularly valuable in the recognition of inflammatory activity in patients who are in remission according to DAS28 scores but have symptoms of tender and/or swollen joints.

show abstract

Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)

Cited by 23 publications

References 51 publications

Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis

Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis

The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission

Contact Info

Product

Resources

About